Wells Fargo & Company Histogen Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.39 - $0.88 $12 - $27	31 Added 100.0%	62 $0
Q2 2023 Aug 15, 2023	BUY	$0.71 - $1.22 $0 - $1	1 Added 3.33%	31 $0
Q1 2023 May 12, 2023	SELL	$0.85 - $1.41 $27 - $45	-32 Reduced 51.61%	30 $0
Q4 2022 Feb 13, 2023	BUY	$0.79 - $1.49 $35 - $67	45 Added 264.71%	62 $0
Q3 2022 Nov 14, 2022	BUY	$1.32 - $3.76 $2 - $7	2 Added 13.33%	17 $0
Q2 2022 Aug 12, 2022	BUY	$2.15 - $8.4 $32 - $126	15 New	15 $0

Ticker HSTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,497,450
Market Cap $524K
Description
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.